Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-16

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hypofractionated Brain Radiationcavity

NCT03561896

Brain Metastases, Adult Cancer Brain

COMPLETED NA

Preoperative Stereotactic Radiosurgery for Brain Metastases

NCT04503772

Brain Metastases

COMPLETED PHASE2

Phase I Dose Escalation in Patients With 1-3 Unresectable Brain Metastases

NCT02080949

Brain Metastases

WITHDRAWN PHASE1

Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease

NCT04114981

Metastatic Malignant Neoplasm in the Brain

ACTIVE_NOT_RECRUITING PHASE3

Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

NCT00863460

Primary Central Nervous System Lymphoma

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemorrhagic Brain Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FSRT Stereotactic radiation therapy

Each cerebral metastasis (hemorrhagic or otherwise) will be treated by radiation

Group Type EXPERIMENTAL

FSRT Stereotactic radiation therapy

Intervention Type RADIATION

For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FSRT Stereotactic radiation therapy

For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age\> 18 years
* Performance Status 0 or 1
* Patient with less than 4 brain metastases \[of a solid tumor, including melanoma, with a histologically proven diagnosis for the solid tumor; Patients who have had a metastasectomy and 1 to 3 brain metastatic lesions are eligible.
* Brain injury (s) measuring between 5 and 30 mm in diameter
* Patient eligible for stereotactic radiotherapy after a decision of the multidisciplinary committee
* Presence of intra-tumor bleeding signals on at least one brain injury before stereotactic irradiation and defined by :

* hyperdense lesion on the non-injected CT (treatment scanner) and / or,
* spontaneously hyperintense lesion on T1 MRI sequences without gadolinium injection and / or,
* lesion with hypo signal on T2 sequences \*
* Absence of meningeal tumor invasion
* Absence of brainstem metastasis
* DS-GPA depending on the histological type (https://brainmetgpa.com/#start):

* Lung Adecarcinoma: DS-GPA 2 or +
* Non-adenocarcinoma lung: DS-GPA 2.5 or +
* Kidney: DS-GPA 2.5 or +
* Breast: DS-GPA 2.5 or +
* Digestive cancer: DS-GPA 3 or +
* Melanoma: DS-GPA 1.5 or +
* Patient without concomitant anti-cancer therapy (chemotherapy, hormone therapy, anti-angiogenic or other anti-cancer treatments). Treatments should be suspended for at least 7 days before the start of FSRT radiotherapy. The treatment can be resumed 7 days after the end of radiotherapy. It's not mandatory to suspend immunotherapy
* Life expectancy estimated at over 6 months
* Patient cooperating sufficiently to perform the treatment with the use of a thermoformed mask
* Patient whose neuropsychological capacities make it possible to follow the requirements of the protocol
* Patient affiliated to a social security scheme
* Patient giving written consent

Exclusion Criteria

* Patient with small cell lung cancer, germ cell tumors, lymphoma, leukemia and multiple myeloma
* Patient with a concomitant neurodegenerative disease
* Any symptoms not attributable to cerebral metastasis or cancerous pathology and requiring long-term use of corticosteroids (regardless of dose)
* Contraindication to brain MRI or gadolinium injection
* Hemorrhagic disorders other than intra-tumor bleeding from brain lesion (s)
* Radiosensitizing systemic disease (Neurofibromatosis ...)
* Thrombocytopenia less than 100,000 cells / mm3
* Anticoagulant treatment, and / or anti-platelet aggregation with curative et prophylaxic dose during FSRT. If treatment can be delayed for at least 5 days before starting FSRT and resumed 2 weeks after completion of FSRT, the patient is eligible.
* Hemorrhagic metastasis (s) of the brainstem
* Planning of the treatment on the target metastasis delivering a dose\> 5 Gy on other metastases concomitant
* Patient with prior cerebral stereotactic irradiation
* History of total brain irradiation
* Any associated geographical, social or psychopathological condition that could compromise the patient's ability to participate in the study
* Participation in a therapeutic trial that could compromise the conduct of study
* Patient deprived of liberty or under guardianship

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No